首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
High MAL2 expression predicts shorter survival in women with triple-negative breast cancer. MAL2的高表达预示着三阴性乳腺癌女性患者的生存期会缩短。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-20 DOI: 10.1007/s12094-024-03514-4
Jędrzej Borowczak, Marek Zdrenka, Weronika Socha, Karol Gostomczyk, Krzysztof Szczerbowski, Mateusz Maniewski, Hanna Andrusewicz, Joanna Łysik-Miśkurka, Tomasz Nowikiewicz, Łukasz Szylberg, Magdalena Bodnar

Introduction: Due to its lack of conventional surface receptors, triple-negative breast cancer (TNBC) is inherently resistant to most targeted therapies. MAL2 overexpression prompts endocytosis, conferring resistance to novel therapeutics. This study explores the role of MAL2 and PD-L1 in TNBC patients' prognosis.

Methods: We performed immunohistochemical analysis on 111 TNBC samples collected from 76 patients and evaluated the expression of MAL2 and PD-1. We expanded the study by including The Cancer Genome Atlas (TCGA) cohort.

Results: MAL2 expression did not correlate with stage, grade, tumor size, lymph node invasion, metastasis, and PD-1 expression. Patients with high MAL2 had significantly lower 5-year survival rates (71.33% vs. 89.59%, p = 0.0224). In the tissue microarray cohort (TMA), node invasions, size, recurrence, and low MAL2 (HR 0.29 [CI 95% 0.087-0.95]; p < 0.05) predicted longer patients' survival. In the TCGA cohort, patients with low MAL2 had significantly longer overall survival and disease-specific survival than patients with high MAL2. Older age and high MAL2 expression were the only independent predictors of shorter patient survival in the BRCA TCGA cohort.

Conclusion: High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.

导言:由于缺乏传统的表面受体,三阴性乳腺癌(TNBC)天生就对大多数靶向疗法具有抗药性。MAL2 的过度表达会促使内吞,从而使其对新型疗法产生抗药性。本研究探讨了MAL2和PD-L1在TNBC患者预后中的作用:我们对从 76 名患者中收集的 111 份 TNBC 样本进行了免疫组化分析,并评估了 MAL2 和 PD-1 的表达。我们将癌症基因组图谱(TCGA)队列纳入其中,扩大了研究范围:结果:MAL2的表达与分期、分级、肿瘤大小、淋巴结侵犯、转移和PD-1的表达无关。MAL2高表达患者的5年生存率明显较低(71.33% vs. 89.59%,p = 0.0224)。在组织微阵列队列(TMA)中,结节侵袭、大小、复发和低MAL2(HR 0.29 [CI 95% 0.087-0.95]; p 结论:高MAL2可预测癌症患者的预后:高MAL2可预测三阴性乳腺癌的不良预后,其表达与PD-1水平和TNBC的临床病理特征无关。
{"title":"High MAL2 expression predicts shorter survival in women with triple-negative breast cancer.","authors":"Jędrzej Borowczak, Marek Zdrenka, Weronika Socha, Karol Gostomczyk, Krzysztof Szczerbowski, Mateusz Maniewski, Hanna Andrusewicz, Joanna Łysik-Miśkurka, Tomasz Nowikiewicz, Łukasz Szylberg, Magdalena Bodnar","doi":"10.1007/s12094-024-03514-4","DOIUrl":"10.1007/s12094-024-03514-4","url":null,"abstract":"<p><strong>Introduction: </strong>Due to its lack of conventional surface receptors, triple-negative breast cancer (TNBC) is inherently resistant to most targeted therapies. MAL2 overexpression prompts endocytosis, conferring resistance to novel therapeutics. This study explores the role of MAL2 and PD-L1 in TNBC patients' prognosis.</p><p><strong>Methods: </strong>We performed immunohistochemical analysis on 111 TNBC samples collected from 76 patients and evaluated the expression of MAL2 and PD-1. We expanded the study by including The Cancer Genome Atlas (TCGA) cohort.</p><p><strong>Results: </strong>MAL2 expression did not correlate with stage, grade, tumor size, lymph node invasion, metastasis, and PD-1 expression. Patients with high MAL2 had significantly lower 5-year survival rates (71.33% vs. 89.59%, p = 0.0224). In the tissue microarray cohort (TMA), node invasions, size, recurrence, and low MAL2 (HR 0.29 [CI 95% 0.087-0.95]; p < 0.05) predicted longer patients' survival. In the TCGA cohort, patients with low MAL2 had significantly longer overall survival and disease-specific survival than patients with high MAL2. Older age and high MAL2 expression were the only independent predictors of shorter patient survival in the BRCA TCGA cohort.</p><p><strong>Conclusion: </strong>High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review. Pembrolizumab 治疗用途的最新进展:简要综述。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-04-24 DOI: 10.1007/s12094-024-03491-8
Vítor Silva, Cristiano Matos

Introduction: Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in immunotherapy, as the first tissue-agnostic cancer treatment.

Objectives: To review pembrolizumab's use in oncology, gather and examine the latest discoveries regarding the effectiveness of pembrolizumab in cancer treatment.

Methodology: A literature review was conducted through PubMed(Medline) from January 2015 to December 2023 using "pembrolizumab", "cancer" and "treatment" as search terms.

Results: Pembrolizumab demonstrated effectiveness as primary treatment for metastatic nonsmall cell lung cancer, unresectable esophageal cancer, head and neck squamous cell carcinoma and alternative treatment for notable triple-negative breast cancer, biliary, colorectal, endometrial, renal cell, cervical carcinoma, and high microsatellite instability or mismatch repair deficiencies tumors. Pediatric applications include treatment for refractory Hodgkin lymphoma.

Conclusion: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.

导言随着作为免疫检查点抑制剂的生物药物的发现,癌症的治疗得到了改善。2017年,美国食品和药物管理局将用于免疫疗法的免疫检查点抑制剂pembrolizumab指定为第一种组织诊断癌症治疗药物:回顾pembrolizumab在肿瘤学中的应用,收集和研究有关pembrolizumab在癌症治疗中有效性的最新发现:以 "pembrolizumab"、"癌症 "和 "治疗 "为检索词,在2015年1月至2023年12月期间通过PubMed(Medline)进行文献综述:Pembrolizumab作为转移性非小细胞肺癌、无法切除的食管癌、头颈部鳞状细胞癌的主要治疗方法,以及显著三阴性乳腺癌、胆道癌、结直肠癌、子宫内膜癌、肾细胞癌、宫颈癌和高微卫星不稳定性或错配修复缺陷肿瘤的替代治疗方法,均显示出有效性。儿科应用包括治疗难治性霍奇金淋巴瘤:尽管存在患者反应不一的挑战,但对 Pembrolizumab 不断发展的研究有助于加深临床理解。Pembrolizumab已成为癌症治疗领域的关键突破,可改善患者的预后和安全性。
{"title":"Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review.","authors":"Vítor Silva, Cristiano Matos","doi":"10.1007/s12094-024-03491-8","DOIUrl":"10.1007/s12094-024-03491-8","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in immunotherapy, as the first tissue-agnostic cancer treatment.</p><p><strong>Objectives: </strong>To review pembrolizumab's use in oncology, gather and examine the latest discoveries regarding the effectiveness of pembrolizumab in cancer treatment.</p><p><strong>Methodology: </strong>A literature review was conducted through PubMed(Medline) from January 2015 to December 2023 using \"pembrolizumab\", \"cancer\" and \"treatment\" as search terms.</p><p><strong>Results: </strong>Pembrolizumab demonstrated effectiveness as primary treatment for metastatic nonsmall cell lung cancer, unresectable esophageal cancer, head and neck squamous cell carcinoma and alternative treatment for notable triple-negative breast cancer, biliary, colorectal, endometrial, renal cell, cervical carcinoma, and high microsatellite instability or mismatch repair deficiencies tumors. Pediatric applications include treatment for refractory Hodgkin lymphoma.</p><p><strong>Conclusion: </strong>Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment benefit of electrochemotherapy for superficial squamous cell carcinoma: a systematic review and single-arm meta-analysis. 电化学疗法对浅表鳞状细胞癌的治疗效果:系统综述和单臂荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-17 DOI: 10.1007/s12094-024-03522-4
Zhuoxia Wu, Chen Tao, Liehao Yang, Yan Yan, Lingfeng Pan, Lianbo Zhang

Objective: Treating aggressive superficial squamous cell carcinoma (SCC) poses challenges due to invasiveness. Palliative care is recommended for inoperable cases with extensive tumors near vital organs, risking disfigurement or functional impairment. Electrochemotherapy (ECT) is an emerging cutaneous tumor treatment, but its efficacy against superficial SCC remains uncertain. This study conducts a systematic review and single-arm meta-analysis to evaluate ECT's effectiveness against superficial SCC and provide current evidence for clinical practice.

Methods: Embase, PubMed and Cochrane Library were searched for studies up to May 2023. The random effects model analyzed complete response (CR) and partial response (PR), with subgroup assessment based on drug dosage, treatment response evaluation, tumor size, primary/recurrent status, and tumor location.

Results: Ten studies involving 162 patients and 208 tumors were included. Pooled CR and PR rates for ECT-treated superficial SCC were 66.5% (95% CI 48.4%-82.5%; I2 = 84%) and 20.3% (95% CI 10.5%-32.3%; I2 = 70%), respectively. Subgroup analysis indicated ECT's superiority in treating primary tumors (PR: 70%, CR: 30%) and tumors ≤ 3 cm (PR: 81.3%, CR: 10.1%) compared to recurrent tumors (PR: 56.7%, CR: 36.5%) and tumors > 3 cm (PR: 45.2%, CR: 34.4%).

Conclusion: This single-arm meta-analysis confirms ECT's efficacy against superficial SCC, especially in primary tumors and those ≤ 3 cm in diameter. The study highlights the impact of tumor location and response evaluation on ECT's benefits, warranting further investigation through additional research.

目的:侵袭性表浅鳞状细胞癌(SCC)因其侵袭性而给治疗带来挑战。对于无法手术且肿瘤广泛靠近重要器官的病例,建议采取姑息治疗,否则有可能导致毁容或功能受损。电化学疗法(ECT)是一种新兴的皮肤肿瘤治疗方法,但其对浅表 SCC 的疗效仍不确定。本研究通过系统综述和单臂荟萃分析,评估电化学疗法对浅表SCC的疗效,为临床实践提供现有证据:方法:检索了Embase、PubMed和Cochrane图书馆截至2023年5月的研究。随机效应模型分析了完全反应(CR)和部分反应(PR),并根据药物剂量、治疗反应评估、肿瘤大小、原发/复发状态和肿瘤位置进行了亚组评估:结果:共纳入 10 项研究,涉及 162 名患者和 208 个肿瘤。ECT治疗浅表性SCC的合计CR和PR率分别为66.5%(95% CI 48.4%-82.5%;I2 = 84%)和20.3%(95% CI 10.5%-32.3%;I2 = 70%)。亚组分析显示,与复发性肿瘤(PR:56.7%,CR:36.5%)和>3 cm的肿瘤(PR:45.2%,CR:34.4%)相比,ECT在治疗原发性肿瘤(PR:70%,CR:30%)和≤3 cm的肿瘤(PR:81.3%,CR:10.1%)方面更具优势:这项单臂荟萃分析证实了 ECT 对浅表 SCC 的疗效,尤其是对原发性肿瘤和直径小于 3 厘米的肿瘤。该研究强调了肿瘤位置和反应评估对ECT疗效的影响,值得通过更多研究进一步探讨。
{"title":"Treatment benefit of electrochemotherapy for superficial squamous cell carcinoma: a systematic review and single-arm meta-analysis.","authors":"Zhuoxia Wu, Chen Tao, Liehao Yang, Yan Yan, Lingfeng Pan, Lianbo Zhang","doi":"10.1007/s12094-024-03522-4","DOIUrl":"10.1007/s12094-024-03522-4","url":null,"abstract":"<p><strong>Objective: </strong>Treating aggressive superficial squamous cell carcinoma (SCC) poses challenges due to invasiveness. Palliative care is recommended for inoperable cases with extensive tumors near vital organs, risking disfigurement or functional impairment. Electrochemotherapy (ECT) is an emerging cutaneous tumor treatment, but its efficacy against superficial SCC remains uncertain. This study conducts a systematic review and single-arm meta-analysis to evaluate ECT's effectiveness against superficial SCC and provide current evidence for clinical practice.</p><p><strong>Methods: </strong>Embase, PubMed and Cochrane Library were searched for studies up to May 2023. The random effects model analyzed complete response (CR) and partial response (PR), with subgroup assessment based on drug dosage, treatment response evaluation, tumor size, primary/recurrent status, and tumor location.</p><p><strong>Results: </strong>Ten studies involving 162 patients and 208 tumors were included. Pooled CR and PR rates for ECT-treated superficial SCC were 66.5% (95% CI 48.4%-82.5%; I<sup>2</sup> = 84%) and 20.3% (95% CI 10.5%-32.3%; I<sup>2</sup> = 70%), respectively. Subgroup analysis indicated ECT's superiority in treating primary tumors (PR: 70%, CR: 30%) and tumors ≤ 3 cm (PR: 81.3%, CR: 10.1%) compared to recurrent tumors (PR: 56.7%, CR: 36.5%) and tumors > 3 cm (PR: 45.2%, CR: 34.4%).</p><p><strong>Conclusion: </strong>This single-arm meta-analysis confirms ECT's efficacy against superficial SCC, especially in primary tumors and those ≤ 3 cm in diameter. The study highlights the impact of tumor location and response evaluation on ECT's benefits, warranting further investigation through additional research.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 转移性耐受性前列腺癌一线系统治疗的疗效比较:系统综述和网络荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-15 DOI: 10.1007/s12094-024-03506-4
Jiahuan Ai, Liuying Jian, Xiaoqin Wen, Xiaotong Huo, Xuanyi Yang, Jie Jiang, Tiantian Zhang

Objectives: No head-to-head trials had been performed to estimate the relative effectiveness of poly ADP-ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) in the first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). We aimed to perform a systematic review and network meta-analysis to evaluate the comparative effectiveness of various systemic treatment agents for patients with mCRPC.

Methods: A comprehensive literature search was conducted for abstracts and full-text articles from the database's inception through April 27, 2023. The study concentrated on assessing radiographic progression-free survival (rPFS) for both overall and homologous recombination repair mutation (HRRm) population, with overall survival (OS) as the secondary measure. Under the Bayesian framework, the overall effect was pooled using the fixed-effects model in base case analysis. Scenario analysis using restricted mean survival time (RMST) methods was performed to test the robustness of the results.

Results: Nine studies with 6,830 patients and 8 unique treatment options were included. Network meta-analysis demonstrated that talazoparib in combination with enzalutamide (TALA + ENZA; overall population, hazard ratio [HR], 0.20; 95% credible interval [CrI]: 0.16-0.26; RMST, 3.51; 95% confidence interval [CI] 2.46-4.60; HRRm population, HR, 0.15; 95% CrI: 0.09-0.23; RMST, 4.14; 95% CI 2.84-5.39) was superior to other treatments in the first-line setting in terms of rPFS. The results of Bayesian framework and RMST models showed consistent efficacy ranks. When extrapolated to overall survival benefit, within the Bayesian framework, olaparib plus abiraterone acetate and prednisone (OLAP + AAP) achieved the highest OS benefit for the overall population, which was not statistically significant when compared to TALA + ENZA. However, TALA + ENZA achieved the highest OS benefit at 3 years by applying RMST.

Conclusions: We suggest that talazoparib in combination with enzalutamide is probably a preferred treatment agent for the overall population and HRRm patients with mCRPC. Given the limitations of network framework and the modeling assumptions undertaken to finalize the analyses, results should be cautiously interpreted.

研究目的目前还没有头对头试验来评估多聚ADP核糖聚合酶抑制剂(PARPi)和雄激素受体信号转导抑制剂(ARSi)在转移性去势抵抗性前列腺癌(mCRPC)一线治疗中的相对有效性。我们旨在进行一项系统性综述和网络荟萃分析,以评估各种系统性治疗药物对 mCRPC 患者的疗效比较:我们对从数据库建立之初到 2023 年 4 月 27 日期间的摘要和全文文章进行了全面的文献检索。研究的重点是评估总体人群和同源重组修复突变(HRRm)人群的放射学无进展生存期(rPFS),并将总生存期(OS)作为次要指标。在贝叶斯框架下,在基础病例分析中使用固定效应模型对总体效应进行汇总。使用受限平均生存时间(RMST)方法进行了情景分析,以检验结果的稳健性:共纳入了 9 项研究、6830 名患者和 8 种独特的治疗方案。网络荟萃分析表明,他唑帕尼联合恩杂鲁胺(TALA + ENZA;总体人群,危险比[HR],0.20;95%可信区间[CrI]:HRRm人群的危险比[HR]为0.15;95%可信区间[CrI]为0.09-0.23;RMST为4.14;95%可信区间[CI]为2.84-5.39)在rPFS方面优于其他一线治疗方法。贝叶斯框架和 RMST 模型的结果显示出一致的疗效等级。在贝叶斯框架内,当推断总生存期获益时,奥拉帕利+醋酸阿比特龙和泼尼松(OLAP+AAP)在总体人群中获得的OS获益最高,与TALA+ENZA相比无统计学意义。然而,通过应用RMST,TALA + ENZA在3年时获得了最高的OS获益:我们认为,对于整体人群和HRRm mCRPC患者而言,talazoparib联合enzalutamide可能是首选治疗药物。鉴于网络框架的局限性以及为最终完成分析而进行的建模假设,对结果的解释应谨慎。
{"title":"Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.","authors":"Jiahuan Ai, Liuying Jian, Xiaoqin Wen, Xiaotong Huo, Xuanyi Yang, Jie Jiang, Tiantian Zhang","doi":"10.1007/s12094-024-03506-4","DOIUrl":"10.1007/s12094-024-03506-4","url":null,"abstract":"<p><strong>Objectives: </strong>No head-to-head trials had been performed to estimate the relative effectiveness of poly ADP-ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) in the first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). We aimed to perform a systematic review and network meta-analysis to evaluate the comparative effectiveness of various systemic treatment agents for patients with mCRPC.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted for abstracts and full-text articles from the database's inception through April 27, 2023. The study concentrated on assessing radiographic progression-free survival (rPFS) for both overall and homologous recombination repair mutation (HRRm) population, with overall survival (OS) as the secondary measure. Under the Bayesian framework, the overall effect was pooled using the fixed-effects model in base case analysis. Scenario analysis using restricted mean survival time (RMST) methods was performed to test the robustness of the results.</p><p><strong>Results: </strong>Nine studies with 6,830 patients and 8 unique treatment options were included. Network meta-analysis demonstrated that talazoparib in combination with enzalutamide (TALA + ENZA; overall population, hazard ratio [HR], 0.20; 95% credible interval [CrI]: 0.16-0.26; RMST, 3.51; 95% confidence interval [CI] 2.46-4.60; HRRm population, HR, 0.15; 95% CrI: 0.09-0.23; RMST, 4.14; 95% CI 2.84-5.39) was superior to other treatments in the first-line setting in terms of rPFS. The results of Bayesian framework and RMST models showed consistent efficacy ranks. When extrapolated to overall survival benefit, within the Bayesian framework, olaparib plus abiraterone acetate and prednisone (OLAP + AAP) achieved the highest OS benefit for the overall population, which was not statistically significant when compared to TALA + ENZA. However, TALA + ENZA achieved the highest OS benefit at 3 years by applying RMST.</p><p><strong>Conclusions: </strong>We suggest that talazoparib in combination with enzalutamide is probably a preferred treatment agent for the overall population and HRRm patients with mCRPC. Given the limitations of network framework and the modeling assumptions undertaken to finalize the analyses, results should be cautiously interpreted.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiomics model for predicting distant metastasis in soft tissue sarcoma of the extremities and trunk treated with surgery. 预测手术治疗的四肢和躯干软组织肉瘤远处转移的放射组学模型。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.1007/s12094-024-03746-4
Miaomiao Yang, Jiyang Jin

Purpose: The aim of this study was to develop a radiomics model based on magnetic resonance imaging (MRI) for predicting metastasis in soft tissue sarcomas (STSs) treated with surgery.

Methods/patients: MRI and clinical data of 73 patients with STSs of the extremities and trunk were obtained from TCIA database and Jiangsu Cancer Hospital as the training set, data of other 40 patients were retrospectively collected at our institution as the external validation set. Radiomics features were extracted from both intratumoral and peritumoral regions of fat-suppressed T2-weighted images (FS-T2WIs) of patients, and 3D ResNet10 was used to extract deep learning features. Recursive feature elimination (RFE) and least absolute shrinkage and selection operator (LASSO) algorithms were used for the selection of features. Based on 4 different sets of features, 5 machine learning algorithms were used to construct intratumor, peritumor, combined intratumor and peritumor radiomics models and deep learning radiomics (DLR) model. The area under the ROC curve (AUC) and Decision curve analysis (DCA) were used to evaluate the ability of models to predict metastasis.

Results and conclusions: Based on 20 selected features from the deep-learning and radiomics features set, the DLR model was able to predict metastasis in the validation dataset, with an AUC of 0.9770. The DCA and Hosmer-Lemeshow test revealed that the DLR model had good clinical benefit and consistency. By getting richer information from MRI, The DLR model is a noninvasive, low-cost method for predicting the risk of metastasis in STSs, and can help develop appropriate treatment programs.

目的:本研究旨在建立一个基于磁共振成像(MRI)的放射组学模型,用于预测接受手术治疗的软组织肉瘤(STS)的转移:从TCIA数据库和江苏省肿瘤医院获得73例四肢和躯干STS患者的MRI和临床数据作为训练集,从本机构回顾性收集另外40例患者的数据作为外部验证集。从患者脂肪抑制T2加权图像(FS-T2WIs)的瘤内和瘤周区域提取放射组学特征,并使用三维ResNet10提取深度学习特征。在选择特征时使用了递归特征消除(RFE)和最小绝对收缩和选择算子(LASSO)算法。根据 4 组不同的特征,使用 5 种机器学习算法构建了瘤内、瘤周、瘤内和瘤周联合放射组学模型以及深度学习放射组学(DLR)模型。ROC曲线下面积(AUC)和决策曲线分析(DCA)用于评估模型预测转移的能力:基于从深度学习和放射组学特征集中选出的 20 个特征,DLR 模型能够预测验证数据集中的转移,AUC 为 0.9770。DCA和Hosmer-Lemeshow检验表明,DLR模型具有良好的临床效益和一致性。通过从核磁共振成像中获取更丰富的信息,DLR模型是一种无创、低成本的预测STS转移风险的方法,有助于制定合适的治疗方案。
{"title":"Radiomics model for predicting distant metastasis in soft tissue sarcoma of the extremities and trunk treated with surgery.","authors":"Miaomiao Yang, Jiyang Jin","doi":"10.1007/s12094-024-03746-4","DOIUrl":"https://doi.org/10.1007/s12094-024-03746-4","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to develop a radiomics model based on magnetic resonance imaging (MRI) for predicting metastasis in soft tissue sarcomas (STSs) treated with surgery.</p><p><strong>Methods/patients: </strong>MRI and clinical data of 73 patients with STSs of the extremities and trunk were obtained from TCIA database and Jiangsu Cancer Hospital as the training set, data of other 40 patients were retrospectively collected at our institution as the external validation set. Radiomics features were extracted from both intratumoral and peritumoral regions of fat-suppressed T2-weighted images (FS-T2WIs) of patients, and 3D ResNet10 was used to extract deep learning features. Recursive feature elimination (RFE) and least absolute shrinkage and selection operator (LASSO) algorithms were used for the selection of features. Based on 4 different sets of features, 5 machine learning algorithms were used to construct intratumor, peritumor, combined intratumor and peritumor radiomics models and deep learning radiomics (DLR) model. The area under the ROC curve (AUC) and Decision curve analysis (DCA) were used to evaluate the ability of models to predict metastasis.</p><p><strong>Results and conclusions: </strong>Based on 20 selected features from the deep-learning and radiomics features set, the DLR model was able to predict metastasis in the validation dataset, with an AUC of 0.9770. The DCA and Hosmer-Lemeshow test revealed that the DLR model had good clinical benefit and consistency. By getting richer information from MRI, The DLR model is a noninvasive, low-cost method for predicting the risk of metastasis in STSs, and can help develop appropriate treatment programs.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upregulation of NPC1 and its association with poor prognosis in gastric cancer. NPC1 的上调及其与胃癌不良预后的关系
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-02 DOI: 10.1007/s12094-024-03490-9
Wei Tang, Jiahua Huang, Guanghua Li, Zhihao Zhou, Zhixiong Wang

Background: The Niemann-Pick disease type C1 (NPC1) protein plays a pivotal role in lipid transport, particularly free cholesterol, within lysosomal/late endosomal membranes. Previous studies have highlighted NPC1 as a promising target for cholesterol trafficking and cancer therapy. Nevertheless, the expression of NPC1 in gastric cancer (GC) and its clinical implications remain unexplored. This study aims to investigate NPC1 expression in GC and its correlation with patient prognosis.

Methods: NPC1 expression levels in GC and normal tissues were assessed using the GEPIA database, and survival analysis was conducted via Kaplan‒Meier Plotter. Evaluation of potential biological effects of NPC1 in GC by protein-protein interaction network and GO, KEGG bioenrichment analysis. Immunohistochemistry was performed on surgical samples collected from 306 GC patients. Correlations between NPC1 expression, clinical characteristics, and patient prognosis were analyzed.

Results: NPC1 mRNA expression was elevated in GC tissues compared to normal tissues (P < 0.05) and significantly associated with poorer prognosis. In our cohort of 306 patients, NPC1 exhibited significant upregulation in GC versus adjacent normal tissues (P = 0.031). High NPC1 expression correlated with adverse clinical characteristics, including lymph node metastasis, distant metastasis, and advanced TNM stage (all P < 0.05). Patients with high NPC1 expression experienced notably shorter overall survival (P < 0.001), particularly in stages III and IV (P = 0.003). Multivariate Cox regression analysis identified high NPC1 expression as an independent prognostic factor for GC patients (HR 1.57, 95% CI 1.14-2.18, P = 0.006). Lastly, an optimized nomogram incorporating NPC1, tumor size, and TNM stage was constructed.

Conclusions: NPC1 expression is upregulated in GC and serves as a pivotal prognostic factor for adverse outcomes in GC patients.

背景:尼曼-皮克病 C1 型(Niemann-Pick disease type C1,NPC1)蛋白在溶酶体/晚期内体膜内的脂质转运,尤其是游离胆固醇转运中起着关键作用。以往的研究强调,NPC1 是胆固醇转运和癌症治疗的有望靶点。然而,NPC1在胃癌(GC)中的表达及其临床意义仍未得到探讨。本研究旨在探讨NPC1在胃癌中的表达及其与患者预后的相关性:方法:利用 GEPIA 数据库评估 NPC1 在 GC 和正常组织中的表达水平,并通过 Kaplan-Meier Plotter 进行生存分析。通过蛋白-蛋白相互作用网络和 GO、KEGG 生物富集分析评估 NPC1 在 GC 中的潜在生物学效应。对 306 例 GC 患者的手术样本进行了免疫组化。分析了NPC1表达、临床特征和患者预后之间的相关性:与正常组织相比,NPC1 mRNA在GC组织中的表达升高(P 结论:NPC1在GC组织中的表达升高,与正常组织相比,NPC1在GC组织中的表达升高:NPC1在GC中表达上调,是GC患者不良预后的关键因素。
{"title":"Upregulation of NPC1 and its association with poor prognosis in gastric cancer.","authors":"Wei Tang, Jiahua Huang, Guanghua Li, Zhihao Zhou, Zhixiong Wang","doi":"10.1007/s12094-024-03490-9","DOIUrl":"10.1007/s12094-024-03490-9","url":null,"abstract":"<p><strong>Background: </strong>The Niemann-Pick disease type C1 (NPC1) protein plays a pivotal role in lipid transport, particularly free cholesterol, within lysosomal/late endosomal membranes. Previous studies have highlighted NPC1 as a promising target for cholesterol trafficking and cancer therapy. Nevertheless, the expression of NPC1 in gastric cancer (GC) and its clinical implications remain unexplored. This study aims to investigate NPC1 expression in GC and its correlation with patient prognosis.</p><p><strong>Methods: </strong>NPC1 expression levels in GC and normal tissues were assessed using the GEPIA database, and survival analysis was conducted via Kaplan‒Meier Plotter. Evaluation of potential biological effects of NPC1 in GC by protein-protein interaction network and GO, KEGG bioenrichment analysis. Immunohistochemistry was performed on surgical samples collected from 306 GC patients. Correlations between NPC1 expression, clinical characteristics, and patient prognosis were analyzed.</p><p><strong>Results: </strong>NPC1 mRNA expression was elevated in GC tissues compared to normal tissues (P < 0.05) and significantly associated with poorer prognosis. In our cohort of 306 patients, NPC1 exhibited significant upregulation in GC versus adjacent normal tissues (P = 0.031). High NPC1 expression correlated with adverse clinical characteristics, including lymph node metastasis, distant metastasis, and advanced TNM stage (all P < 0.05). Patients with high NPC1 expression experienced notably shorter overall survival (P < 0.001), particularly in stages III and IV (P = 0.003). Multivariate Cox regression analysis identified high NPC1 expression as an independent prognostic factor for GC patients (HR 1.57, 95% CI 1.14-2.18, P = 0.006). Lastly, an optimized nomogram incorporating NPC1, tumor size, and TNM stage was constructed.</p><p><strong>Conclusions: </strong>NPC1 expression is upregulated in GC and serves as a pivotal prognostic factor for adverse outcomes in GC patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer. 杯突相关基因 UBE2D2 可作为泛癌症的免疫治疗和预后生物标志物。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-04 DOI: 10.1007/s12094-024-03495-4
Yao Fei, Danping Cao, Runyu Dong, Yanna Li, Zhixiong Wang, Peng Gao, Menglin Zhu, Xiaoming Wang, Xueliang Zuo, Juan Cai

Background: Cuproptosis, as a unique modality of regulated cell death, requires the involvement of ubiquitin-binding enzyme UBE2D2. However, the prognostic and immunotherapeutic values of UBE2D2 in pan-cancer remain largely unknown.

Methods: Using UCSC Xena, TIMER, Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA) databases, we aimed to explore the differential expression pattern of UBE2D2 across multiple cancer types and to evaluate its association with patient prognosis, clinical features, and genetic variations. The association between UBE2D2 and immunotherapy response was assessed by gene set enrichment analysis, tumor microenvironment, immune gene co-expression and drug half maximal inhibitory concentration (IC50) analysis.

Results: The mRNA and protein levels of UBE2D2 were markedly elevated in most cancer types, and UBE2D2 exhibited prognostic significance in liver hepatocellular carcinoma (LIHC), kidney chromophobe (KICH), uveal melanomas (UVM), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and kidney renal papillary cell carcinoma (KIRP). UBE2D2 expression was correlated with clinical features, tumor mutation burden, microsatellite instability, and anti-tumor drug resistance in several tumor types. Gene enrichment analysis showed that UBE2D2 was significantly associated with immune-related pathways. The expression level of UBE2D2 was correlated with immune cell infiltration, including CD4 + T cells、Macrophages M2、CD8 + T cells in pan-cancer. PDCD1, CD274 and CTLA4 expression levels were positively correlated with UBE2D2 level in multiple cancers.

Conclusions: We comprehensively investigated the potential value of UBE2D2 as a prognostic and immunotherapeutic predictor for pan-cancer, providing a novel insight for cancer immunotherapy.

背景:杯突作为一种独特的细胞死亡调节方式,需要泛素结合酶UBE2D2的参与。然而,UBE2D2 在泛癌症中的预后和免疫治疗价值在很大程度上仍不为人所知:我们利用 UCSC Xena、TIMER、临床肿瘤蛋白质组学分析联盟(CPTAC)和人类蛋白质图谱(HPA)数据库,旨在探索 UBE2D2 在多种癌症类型中的差异表达模式,并评估其与患者预后、临床特征和遗传变异的关联。我们通过基因组富集分析、肿瘤微环境、免疫基因共表达和药物半数最大抑制浓度(IC50)分析评估了UBE2D2与免疫治疗反应之间的关联:UBE2D2在肝肝细胞癌(LIHC)、肾嗜铬细胞瘤(KICH)、葡萄膜黑色素瘤(UVM)、宫颈鳞癌和宫颈内膜腺癌(CESC)以及肾肾乳头状细胞癌(KIRP)中具有预后意义。UBE2D2的表达与几种肿瘤类型的临床特征、肿瘤突变负荷、微卫星不稳定性和抗肿瘤药物耐药性相关。基因富集分析表明,UBE2D2与免疫相关通路密切相关。UBE2D2的表达水平与免疫细胞浸润相关,包括泛癌中的CD4 + T细胞、巨噬细胞M2、CD8 + T细胞。在多种癌症中,PDCD1、CD274和CTLA4的表达水平与UBE2D2水平呈正相关:我们全面研究了UBE2D2作为泛癌症预后和免疫治疗预测因子的潜在价值,为癌症免疫治疗提供了新的视角。
{"title":"The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.","authors":"Yao Fei, Danping Cao, Runyu Dong, Yanna Li, Zhixiong Wang, Peng Gao, Menglin Zhu, Xiaoming Wang, Xueliang Zuo, Juan Cai","doi":"10.1007/s12094-024-03495-4","DOIUrl":"10.1007/s12094-024-03495-4","url":null,"abstract":"<p><strong>Background: </strong>Cuproptosis, as a unique modality of regulated cell death, requires the involvement of ubiquitin-binding enzyme UBE2D2. However, the prognostic and immunotherapeutic values of UBE2D2 in pan-cancer remain largely unknown.</p><p><strong>Methods: </strong>Using UCSC Xena, TIMER, Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA) databases, we aimed to explore the differential expression pattern of UBE2D2 across multiple cancer types and to evaluate its association with patient prognosis, clinical features, and genetic variations. The association between UBE2D2 and immunotherapy response was assessed by gene set enrichment analysis, tumor microenvironment, immune gene co-expression and drug half maximal inhibitory concentration (IC50) analysis.</p><p><strong>Results: </strong>The mRNA and protein levels of UBE2D2 were markedly elevated in most cancer types, and UBE2D2 exhibited prognostic significance in liver hepatocellular carcinoma (LIHC), kidney chromophobe (KICH), uveal melanomas (UVM), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and kidney renal papillary cell carcinoma (KIRP). UBE2D2 expression was correlated with clinical features, tumor mutation burden, microsatellite instability, and anti-tumor drug resistance in several tumor types. Gene enrichment analysis showed that UBE2D2 was significantly associated with immune-related pathways. The expression level of UBE2D2 was correlated with immune cell infiltration, including CD4 + T cells、Macrophages M2、CD8 + T cells in pan-cancer. PDCD1, CD274 and CTLA4 expression levels were positively correlated with UBE2D2 level in multiple cancers.</p><p><strong>Conclusions: </strong>We comprehensively investigated the potential value of UBE2D2 as a prognostic and immunotherapeutic predictor for pan-cancer, providing a novel insight for cancer immunotherapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. 来伐替尼、经动脉化疗栓塞和PD-1/L1抑制剂对晚期肝细胞癌的临床疗效:系统综述和网络荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-04-26 DOI: 10.1007/s12094-024-03458-9
YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang

Background: Currently, the effectiveness of TACE, Lenvatinib, and PD-1/L1 inhibitors used alone or in combination has been thoroughly reported. However, the differences in effectiveness between these treatment protocols require further verification. To this end, this study employs a Bayesian network meta-analysis to compare the efficacy and safety of TACE, Lenvatinib, and PD-1/L1 inhibitors, whether administered by monotherapy or in combination, providing evidence-based medicine for the treatment of unresectable HCC.

Purpose: This study employed a network meta-analysis to evaluate the efficacy and safety of trans-arterial chemoembolization (TACE), Programmed Cell Death Protein/Ligand 1 (PD-1/L1) inhibitors, and Lenvatinib in the treatment of advanced HCC.

Methods: Literature on the treatment of advanced HCC with TACE, PD-1/L1 inhibitors, and Lenvatinib was searched for in both Chinese and English databases, including PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, CNKI, and Wanfang. Two researchers conducted independent screening and data extraction, and the meta-analysis was performed using R language with the gemtc package.

Results: After retrieval and screening, a total of 21 articles were included, involving 2052 participants and six treatment modalities: Lenvatinib (L), TACE (T), TACE + Lenvatinib (TL), Lenvatinib + PD-1/L1 inhibitors (LP), TACE + Lenvatinib + PD-1/L1 inhibitors (TLP), and TACE + PD-1/L1 inhibitors (TP). In terms of objective response rate (ORR), the TLP regimen provided the optimal effect. In predicting the best ORR, TLP had the highest (75.5%) probability. In terms of disease control rate (DCR), the TLP regimen showed the best effect. In predicting the best DCR, the TLP again offered the highest (76.1%) probability. In terms of overall survival (OS), the best outcome was observed in the TLP protocol. In predicting the best OS, the TLP holds the highest (86.00%) probability. Furthermore, the best outcome in progression-free survival (PFS) was found in the TLP regimen. In predicting the best PFS, the TLP still holds the highest (97.0%) result.

Conclusion: The combination of TACE, Lenvatinib, and PD-1/L1 inhibitors appears to provide the maximum benefit for inoperable HCC patients.

背景目前,关于TACE、伦伐替尼和PD-1/L1抑制剂单独或联合使用的有效性已有详尽报道。然而,这些治疗方案之间的有效性差异需要进一步验证。为此,本研究采用贝叶斯网络荟萃分析比较了 TACE、Lenvatinib 和 PD-1/L1 抑制剂单药或联合用药的疗效和安全性,为治疗不可切除的 HCC 提供循证医学依据。目的:本研究采用网络荟萃分析评估经动脉化疗栓塞(TACE)、程序性细胞死亡蛋白/配体1(PD-1/L1)抑制剂和仑伐替尼治疗晚期HCC的有效性和安全性:在PubMed、EMBASE、ClinicalTrials.gov、Cochrane Library、CNKI和万方等中英文数据库中检索有关TACE、PD-1/L1抑制剂和仑伐替尼治疗晚期HCC的文献。两名研究人员进行了独立的筛选和数据提取,并使用 R 语言和 gemtc 软件包进行了荟萃分析:经过检索和筛选,共纳入21篇文章,涉及2052名参与者和6种治疗方式:列伐替尼(L)、TACE(T)、TACE+列伐替尼(TL)、列伐替尼+PD-1/L1抑制剂(LP)、TACE+列伐替尼+PD-1/L1抑制剂(TLP)和TACE+PD-1/L1抑制剂(TP)。从客观反应率(ORR)来看,TLP方案的疗效最佳。在预测最佳ORR方面,TLP的概率最高(75.5%)。在疾病控制率(DCR)方面,TLP疗法的效果最佳。在预测最佳疾病控制率方面,TLP再次提供了最高(76.1%)的概率。在总生存期(OS)方面,TLP方案的疗效最佳。在预测最佳 OS 方面,TLP 的概率最高(86.00%)。此外,TLP 方案的无进展生存期(PFS)也是最好的。在预测最佳无进展生存期方面,TLP方案的结果仍然最高(97.0%):结论:TACE、伦伐替尼和PD-1/L1抑制剂的联合治疗似乎能为无法手术的HCC患者带来最大益处。
{"title":"Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.","authors":"YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang","doi":"10.1007/s12094-024-03458-9","DOIUrl":"10.1007/s12094-024-03458-9","url":null,"abstract":"<p><strong>Background: </strong>Currently, the effectiveness of TACE, Lenvatinib, and PD-1/L1 inhibitors used alone or in combination has been thoroughly reported. However, the differences in effectiveness between these treatment protocols require further verification. To this end, this study employs a Bayesian network meta-analysis to compare the efficacy and safety of TACE, Lenvatinib, and PD-1/L1 inhibitors, whether administered by monotherapy or in combination, providing evidence-based medicine for the treatment of unresectable HCC.</p><p><strong>Purpose: </strong>This study employed a network meta-analysis to evaluate the efficacy and safety of trans-arterial chemoembolization (TACE), Programmed Cell Death Protein/Ligand 1 (PD-1/L1) inhibitors, and Lenvatinib in the treatment of advanced HCC.</p><p><strong>Methods: </strong>Literature on the treatment of advanced HCC with TACE, PD-1/L1 inhibitors, and Lenvatinib was searched for in both Chinese and English databases, including PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, CNKI, and Wanfang. Two researchers conducted independent screening and data extraction, and the meta-analysis was performed using R language with the gemtc package.</p><p><strong>Results: </strong>After retrieval and screening, a total of 21 articles were included, involving 2052 participants and six treatment modalities: Lenvatinib (L), TACE (T), TACE + Lenvatinib (TL), Lenvatinib + PD-1/L1 inhibitors (LP), TACE + Lenvatinib + PD-1/L1 inhibitors (TLP), and TACE + PD-1/L1 inhibitors (TP). In terms of objective response rate (ORR), the TLP regimen provided the optimal effect. In predicting the best ORR, TLP had the highest (75.5%) probability. In terms of disease control rate (DCR), the TLP regimen showed the best effect. In predicting the best DCR, the TLP again offered the highest (76.1%) probability. In terms of overall survival (OS), the best outcome was observed in the TLP protocol. In predicting the best OS, the TLP holds the highest (86.00%) probability. Furthermore, the best outcome in progression-free survival (PFS) was found in the TLP regimen. In predicting the best PFS, the TLP still holds the highest (97.0%) result.</p><p><strong>Conclusion: </strong>The combination of TACE, Lenvatinib, and PD-1/L1 inhibitors appears to provide the maximum benefit for inoperable HCC patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling sex-based geographical disparities in myelodysplastic syndrome mortality trends in Spain (1999-2022). 揭示西班牙骨髓增生异常综合征死亡率趋势中基于性别的地域差异(1999-2022 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-19 DOI: 10.1007/s12094-024-03503-7
Reyes María Martín-Rojas, Lucía Cayuela, Francisco Martín-Domínguez, Aurelio Cayuela

Aim: To comprehensively analyze trends in myelodysplastic neoplasm (MDS) mortality across Spain (1999-2022), examining sex and regional differences.

Methods: We analyzed nationwide death records and population data, calculating age-standardized mortality rates (ASMRs) and standardized mortality ratios (SMRs) stratified by sex and Autonomous Community (AC). Joinpoint regression identified significant shifts in trends.

Results: Across Spain, MDS mortality risk varied among men, with rates ranging from 1.08 to 4.38 per 100,000 across regions, while women's rates ranged from 1.23 to 2.02. Five regions had higher risks than the national average, while six had lower risks. Joinpoint analysis revealed three periods nationally: a decline until 2008, and an increase until 2017, followed by a significant decrease. Despite the overall stable national trend (-0.5% annual change), significant regional variations emerged. Andalusia stood out with a worrying increase in MDS mortality, while Aragon and Murcia demonstrated promising declines. Extremadura displayed a unique trajectory with an initial rise followed by stabilization, while Galicia exhibited a contrasting trend with an initial decline and subsequent increase. Notably, men consistently faced a higher risk of MDS mortality compared to women, with significant disparities across regions. Extremadura, in particular, showed a marked difference in risk between genders.

Conclusion: MDS mortality trends in Spain are complex, and influenced by gender, region, and time. Further research is needed to understand regional disparities, recent national decline, and higher risk in specific demographics. Tailored interventions based on local factors and targeted research are crucial to address these complexities and improve patient outcomes.

目的:全面分析西班牙骨髓增生异常肿瘤(MDS)死亡率的趋势(1999-2022 年),研究性别和地区差异:我们分析了全国范围内的死亡记录和人口数据,计算了按性别和自治区(AC)分层的年龄标准化死亡率(ASMRs)和标准化死亡率(SMRs)。连接点回归确定了趋势的重大变化:在整个西班牙,男性的 MDS 死亡风险各不相同,各地区的比率从每 10 万人中 1.08 例到 4.38 例不等,而女性的比率则从 1.23 例到 2.02 例不等。五个地区的风险高于全国平均水平,而六个地区的风险较低。连接点分析显示,全国有三个时期:2008 年前下降,2017 年前上升,随后大幅下降。尽管全国总体趋势稳定(年变化率为-0.5%),但各地区之间出现了显著差异。安达卢西亚的 MDS 死亡率令人担忧地上升,而阿拉贡和穆尔西亚则出现了可喜的下降。埃斯特雷马杜拉呈现出一种独特的轨迹,即最初上升,随后趋于稳定,而加利西亚则呈现出一种相反的趋势,即最初下降,随后上升。值得注意的是,与女性相比,男性面临的 MDS 死亡风险一直较高,各地区之间存在显著差异。埃斯特雷马杜拉地区的性别风险差异尤为明显:西班牙的 MDS 死亡率趋势非常复杂,受到性别、地区和时间的影响。需要进一步开展研究,以了解地区差异、最近的全国性下降以及特定人群的高风险。基于当地因素的定制干预措施和有针对性的研究对于解决这些复杂问题和改善患者预后至关重要。
{"title":"Unveiling sex-based geographical disparities in myelodysplastic syndrome mortality trends in Spain (1999-2022).","authors":"Reyes María Martín-Rojas, Lucía Cayuela, Francisco Martín-Domínguez, Aurelio Cayuela","doi":"10.1007/s12094-024-03503-7","DOIUrl":"10.1007/s12094-024-03503-7","url":null,"abstract":"<p><strong>Aim: </strong>To comprehensively analyze trends in myelodysplastic neoplasm (MDS) mortality across Spain (1999-2022), examining sex and regional differences.</p><p><strong>Methods: </strong>We analyzed nationwide death records and population data, calculating age-standardized mortality rates (ASMRs) and standardized mortality ratios (SMRs) stratified by sex and Autonomous Community (AC). Joinpoint regression identified significant shifts in trends.</p><p><strong>Results: </strong>Across Spain, MDS mortality risk varied among men, with rates ranging from 1.08 to 4.38 per 100,000 across regions, while women's rates ranged from 1.23 to 2.02. Five regions had higher risks than the national average, while six had lower risks. Joinpoint analysis revealed three periods nationally: a decline until 2008, and an increase until 2017, followed by a significant decrease. Despite the overall stable national trend (-0.5% annual change), significant regional variations emerged. Andalusia stood out with a worrying increase in MDS mortality, while Aragon and Murcia demonstrated promising declines. Extremadura displayed a unique trajectory with an initial rise followed by stabilization, while Galicia exhibited a contrasting trend with an initial decline and subsequent increase. Notably, men consistently faced a higher risk of MDS mortality compared to women, with significant disparities across regions. Extremadura, in particular, showed a marked difference in risk between genders.</p><p><strong>Conclusion: </strong>MDS mortality trends in Spain are complex, and influenced by gender, region, and time. Further research is needed to understand regional disparities, recent national decline, and higher risk in specific demographics. Tailored interventions based on local factors and targeted research are crucial to address these complexities and improve patient outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaginal micro-environment disorder promotes malignant prognosis of low-grade cervical intraepithelial neoplasia: a prospective community cohort study in Shanxi Province, China. 阴道微环境紊乱对低度宫颈上皮内瘤变恶性预后的影响:一项在中国山西省进行的前瞻性社区队列研究。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-05-21 DOI: 10.1007/s12094-024-03524-2
Jiamin Liu, Nan Hu, Xiao Zheng, Huimin Li, Kailu Zhao, Jiahao Wang, Mingxuan Zhang, Le Zhang, Li Song, Yuanjing Lyu, Meng Cui, Ling Ding, Jintao Wang

Purpose: Emerging evidence suggests that vaginal micro-environment disorder is closely related to the development of cervical lesions. Low-grade cervical intraepithelial neoplasia (CIN1), as an early stage of cervical lesions, exhibits a high risk of progressing to high-grade lesions or even cervical cancer. However, the effect of vaginal micro-environment on the malignant prognosis of CIN1 remains uncertain.

Methods: A total of 504 patients diagnosed with CIN1 by pathology, who were from the population-based cohorts established in Shanxi Province, China, were enrolled and followed up for 2 years. Micro-environmental factors such as vaginal pH, cleanliness, hydrogen peroxide (H2O2), β-glucuronidase (GUSB), leucocyte esterase (LE), and sialidase (SNA) were detected to evaluate their effect on the malignant prognosis of CIN1.

Results: Abnormal vaginal pH (HR = 1.472, 95%CI 1.071-2.022), cleanliness (HR = 1.446, 95%CI 1.067-1.960), H2O2 (HR = 1.525, 95%CI 1.155-2.013), GUSB (HR = 1.739, 95%CI 1.235-2.448), LE (HR = 1.434, 95%CI 1.038-1.981), and SNA (HR = 1.411, 95%CI 1.065-1.870) could promote a higher incidence of CIN1 malignant prognosis, and the combined effects of these micro-environmental factors resulted in a nearly twofold increased risk (HR = 2.492, 95%CI 1.773-3.504) compared to any single factor alone, especially under the high-risk human papillomavirus (HR-HPV) infection. Notably, the cumulative incidence of malignant prognosis for CIN1 gradually increased during the early follow-up period, reaching its peak at approximately 8 months, and then stabilizing.

Conclusion: Vaginal micro-environment disorder could promote CIN1 malignant prognosis, particularly in HR-HPV-infected women. Taking micro-environmental factors as the breakthrough, our study provides a feasible vision for preventing early stage cervical lesions.

目的:新的证据表明,阴道微环境紊乱与宫颈病变的发展密切相关。低度宫颈上皮内瘤变(CIN1)作为宫颈病变的早期阶段,具有向高级别病变甚至宫颈癌发展的高风险。然而,阴道微环境对 CIN1 恶性预后的影响仍不确定:方法:从中国山西省建立的人群队列中选取了504例经病理诊断为CIN1的患者,并对其进行了为期2年的随访。研究人员检测了阴道pH值、清洁度、过氧化氢(H2O2)、β-葡糖醛酸酶(GUSB)、白细胞酯酶(LE)和硅糖苷酶(SNA)等微环境因素,以评估它们对CIN1恶性预后的影响:阴道pH值异常(HR = 1.472,95%CI 1.071-2.022)、清洁度(HR = 1.446,95%CI 1.067-1.960)、H2O2(HR = 1.525,95%CI 1.155-2.013)、GUSB(HR = 1.739,95%CI 1.235-2.448)、LE(HR = 1.434,95%CI 1.038-1.981)和 SNA(HR = 1.411,95%CI 1.065-1.这些微环境因素的联合作用导致风险增加了近两倍(HR = 2.492,95%CI 1.773-3.504),与单独任何一个因素相比都是如此,尤其是在高危人乳头瘤病毒(HR-HPV)感染的情况下。值得注意的是,CIN1恶性预后的累积发生率在早期随访期间逐渐增加,在约8个月时达到高峰,随后趋于稳定:结论:阴道微环境紊乱可促进CIN1恶性预后,尤其是感染HR-HPV的妇女。以微环境因素为突破口,我们的研究为预防早期宫颈病变提供了可行的思路。
{"title":"Vaginal micro-environment disorder promotes malignant prognosis of low-grade cervical intraepithelial neoplasia: a prospective community cohort study in Shanxi Province, China.","authors":"Jiamin Liu, Nan Hu, Xiao Zheng, Huimin Li, Kailu Zhao, Jiahao Wang, Mingxuan Zhang, Le Zhang, Li Song, Yuanjing Lyu, Meng Cui, Ling Ding, Jintao Wang","doi":"10.1007/s12094-024-03524-2","DOIUrl":"10.1007/s12094-024-03524-2","url":null,"abstract":"<p><strong>Purpose: </strong>Emerging evidence suggests that vaginal micro-environment disorder is closely related to the development of cervical lesions. Low-grade cervical intraepithelial neoplasia (CIN1), as an early stage of cervical lesions, exhibits a high risk of progressing to high-grade lesions or even cervical cancer. However, the effect of vaginal micro-environment on the malignant prognosis of CIN1 remains uncertain.</p><p><strong>Methods: </strong>A total of 504 patients diagnosed with CIN1 by pathology, who were from the population-based cohorts established in Shanxi Province, China, were enrolled and followed up for 2 years. Micro-environmental factors such as vaginal pH, cleanliness, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), β-glucuronidase (GUSB), leucocyte esterase (LE), and sialidase (SNA) were detected to evaluate their effect on the malignant prognosis of CIN1.</p><p><strong>Results: </strong>Abnormal vaginal pH (HR = 1.472, 95%CI 1.071-2.022), cleanliness (HR = 1.446, 95%CI 1.067-1.960), H<sub>2</sub>O<sub>2</sub> (HR = 1.525, 95%CI 1.155-2.013), GUSB (HR = 1.739, 95%CI 1.235-2.448), LE (HR = 1.434, 95%CI 1.038-1.981), and SNA (HR = 1.411, 95%CI 1.065-1.870) could promote a higher incidence of CIN1 malignant prognosis, and the combined effects of these micro-environmental factors resulted in a nearly twofold increased risk (HR = 2.492, 95%CI 1.773-3.504) compared to any single factor alone, especially under the high-risk human papillomavirus (HR-HPV) infection. Notably, the cumulative incidence of malignant prognosis for CIN1 gradually increased during the early follow-up period, reaching its peak at approximately 8 months, and then stabilizing.</p><p><strong>Conclusion: </strong>Vaginal micro-environment disorder could promote CIN1 malignant prognosis, particularly in HR-HPV-infected women. Taking micro-environmental factors as the breakthrough, our study provides a feasible vision for preventing early stage cervical lesions.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1